세포생물학 시장 예측(-2030년) : 제품, 기술, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Cell Biology Market is accounted for $20.6 billion in 2023 and is expected to reach $59.0 billion by 2030 growing at a CAGR of 16.2% during the forecast period. The field of science that studies the basic building block of life, the cell, is called cell biology, sometimes referred to as cytology. The smallest autonomous entities found in living beings, cells, are studied in terms of their form, function, and behaviour. Moreover, cell biology explores the complex processes that control cell development, division, communication, and contact with the outside world. It includes research on metabolic, DNA replication, gene expression, and cell signalling systems.

According to GLOBOCAN, cancer cases would increase to almost 30 million by 2040, up from 19.3 million cases and ten million cancer deaths in 2020.

Market Dynamics:

Driver:

Government funding and support

Cell biology research requires government funding and support to advance scientific discovery, medical advancements, and biotechnological developments. Additionally, to support research efforts, buy cutting-edge equipment, and hire scientists, governments provide funding to academic institutions, research centers, and biotech firms. Moreover, a greater comprehension of basic cellular processes, the generation of cutting-edge biotechnological products, and an acceleration of cell biology discoveries are all made possible by this financial support. Furthermore, government monitoring and ethical rules also assist in ensuring that cell biology research is carried out ethically and with the highest care for ethical, legal, and safety standards, eventually benefiting society as a whole, thereby driving the market size.

Restraint:

High expenses and patent issues

Research in cell biology necessitates expensive equipment, reagents, and specialist knowledge. Moreover, access to resources may be hampered by the high expense of conducting cell biology experiments and buying the necessary equipment and supplies, especially for smaller research institutes or groups with little financing. Additionally, the development and commercialization of cell biology products and technology may be hampered by intellectual property rights and patent disputes. Furthermore, certain areas of cell biology research can experience delays and financial losses due to legal complications and ownership disputes. Hence, as a result, these factors may negatively impact market size.

Opportunity:

New Innovative tools and techniques

Cell biology research and applications have changed as a result of technological developments. High-resolution microscopy, single-cell sequencing, and gene editing platforms like CRISPR-Cas9 have all transformed our understanding of how cells function. Additionally, with the support of these tools, researchers can examine cells in unprecedented depth, revealing complex molecular processes that have revolutionized the fields of genetics, cancer research, regenerative medicine, and drug discovery. Furthermore, the speed of discovery has also been accelerated by the streamlining of experiments and data processing enabled by automation and big data analysis. Therefore, technology advancements in cell biology are advancing the boundaries of knowledge and have the potential to solve challenging health issues which thus propel the market expansion.

Threat:

Lack of standardization and skilled professionals

The use of complicated protocols and techniques in cell biology research frequently results in variability and difficulties with reproducibility. Moreover, the dependability and comparability of results can be hampered by unstandardized procedures and differences in experimental circumstances, which can have an adverse effect on the field's overall advancement. Furthermore, the rate of research and growth in the industry, however, may be slowed down by a lack of qualified professionals in certain fields of cell biology.

COVID-19 Impact

Cell biology research has suffered a number of obstacles as a result of the COVID-19 pandemic. Disruptions have affected laboratories all across the world, including temporary closures, access restrictions, and reduced worker numbers. Additionally, this has slowed down cell biology research by causing delays and difficulties in ongoing experiments and data collection. Moreover, COVID-19 research has taken up more time, money, and staff than other fields of study, which has slowed the progress of cell biology. Collaborations, the sharing of ideas and scientific advancements have all been hampered by the restrictions placed by travel restrictions and social distance-reducing policies. Therefore, the normal operation and advancement of cell biology research have generally been significantly hindered by the pandemic.

The Molecular Biology Kits segment is expected to be the largest during the forecast period

The Molecular Biology Kits segment is estimated to hold the largest share, due to a wide range of already prepared reagent kits and instruments intended for molecular analysis and molecular manipulation of biological molecules. These tools are necessary for many molecular biology procedures, including DNA and RNA extraction, PCR, gene expression analysis, and DNA sequencing. They make it easier for researchers to conduct tests accurately and quickly by streamlining and simplifying laboratory operations. By facilitating access to molecular studies and advancing genetic, genomic, and personalized medicine research, molecular biology kits have transformed the discipline and advanced our understanding of cellular functions and how they affect health and illness.

The Gene Editing Technologies segment is expected to have the highest CAGR during the forecast period

The Gene Editing Technologies segment is anticipated to have highest CAGR during the forecast period, due to potent tools and techniques that allow for precise manipulation of an organism's DNA. Additionally, popular methods include TALENs, zinc finger nucleases, and CRISPR-Cas9. In order to study gene function, treat genetic abnormalities, and produce genetically modified creatures for research or therapeutic purposes, these technologies enable specific modifications in genes. Furthermore, it has also provided previously unattainable insights into the molecular mechanisms underlying various biological processes and holds tremendous promise for the treatment of genetic diseases and the advancement of biotechnology applications. Therefore, these factors significantly propel the market expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to infrastructure for healthcare and research and development are the main goals of these efforts. Additionally, Cell biology research is funded by the National Health and Medical Research Council of Australia and Department of Biotechnology in India provides funding and support for cell biology research initiatives. Furthermore, these programs seek to build scientific capacity, draw talent, and encourage the development of cutting-edge cell biology technology, ultimately enhancing healthcare, fostering economic growth, and boosting Asia-Pacific.

Region with highest CAGR:

North America is expected to witness highest CAGR over the projection period. It acts as the center for cutting-edge research, with several universities, research centers, and biotechnology firms setting the standard for cellular research and innovation. Additionally, the area has been essential in the development of personalized medicine, stem cell research, and gene editing technologies, which have advanced our understanding of diseases and led to the creation of innovative therapies. Furthermore, this healthy ecosystem has substantially boosted the growth and competitiveness of the global cell biology market, in addition to advancing scientific understanding.

Key players in the market

Some of the key players in the Cell Biology Market include: Novartis, Pfizer, HiMedia Laboratories, BD Biosciences, Thermo Fisher Scientific, GE Healthcare Life Sciences, Vertex Pharmaceuticals, Qiagen, Illumina, Bio-Rad Laboratories, Lonza Group, Amgen, Roche, Johnson & Johnson and PerkinElmer.

Key Developments:

In September 2023, Ginkgo Bioworks announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates.

In August 2023, Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based Biopharmaceutical Company focused on the discovery, development, and commercialization of precision medicines for kidney diseases.

In July 2023, Novartis' acquisition of biotech company DTx Pharma boosts its neuroscience pipeline and expands its capabilities in RNA-based therapeutics.

Products Covered:

• Microscopy and Imaging
• Cell Analysis Instruments
• Molecular Biology Kits
• Cell-based Assays
• Other Products

Technologies Covered:

• Next-Generation Sequencing (NGS)
• Gene Editing Technologies
• Bioinformatics and Computational Tools
• Cell Culture and Tissue Engineering
• Proteomics and Protein Analysis
• Other Technologies

Applications Covered:

• Neuroscience
• Immunology
• Stem Cell Research
• Genetics and Genomics
• Cell Therapy and Immunotherapy
• Virology
• Other Applications

End Users Covered:

• Contract Research Organizations (CROs)
• Academic and Research Institutions
• Hospitals and Healthcare Providers
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies
• Stem Cell and Regenerative Medicine Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cell Biology Market, By Product

• 5.1 Introduction
• 5.2 Microscopy and Imaging
  • 5.2.1 Electron Microscopes
  • 5.2.2 Fluorescence Microscopes
• 5.3 Cell Analysis Instruments
• 5.4 Molecular Biology Kits
• 5.5 Cell-based Assays
• 5.6 Other Products

6 Global Cell Biology Market, By Technology

• 6.1 Introduction
• 6.2 Next-Generation Sequencing (NGS)
• 6.3 Gene Editing Technologies
• 6.4 Bioinformatics and Computational Tools
• 6.5 Cell Culture and Tissue Engineering
• 6.6 Proteomics and Protein Analysis
• 6.7 Other Technologies

7 Global Cell Biology Market, By Application

• 7.1 Introduction
• 7.2 Neuroscience
• 7.3 Immunology
• 7.4 Stem Cell Research
• 7.5 Genetics and Genomics
• 7.6 Cell Therapy and Immunotherapy
• 7.7 Virology
• 7.8 Other Applications

8 Global Cell Biology Market, By End User

• 8.1 Introduction
• 8.2 Contract Research Organizations (CROs)
• 8.3 Academic and Research Institutions
• 8.4 Hospitals and Healthcare Providers
• 8.5 Clinical Laboratories
• 8.6 Pharmaceutical and Biotechnology Companies
• 8.7 Stem Cell and Regenerative Medicine Companies
• 8.8 Other End Users

9 Global Cell Biology Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Novartis
• 11.2 Pfizer
• 11.3 HiMedia Laboratories
• 11.4 BD Biosciences
• 11.5 Thermo Fisher Scientific
• 11.6 GE Healthcare Life Sciences
• 11.7 Vertex Pharmaceuticals
• 11.8 Qiagen
• 11.9 Illumina
• 11.10 Bio-Rad Laboratories
• 11.11 Lonza Group
• 11.12 Amgen
• 11.13 Roche
• 11.14 Johnson & Johnson
• 11.15 PerkinElmer